eXoZymes Partners With B2i Digital to Advance Cell-Free Biomanufacturing Platform

eXoZymes Inc. has been named a B2i Digital Featured Company, bringing attention to its innovative cell-free, AI-guided enzyme platform that represents a significant advancement in sustainable biomanufacturing. The partnership will showcase eXoZymes' technology to B2i Digital's sophisticated investor community, highlighting the company's approach to overcoming scale-up limitations in traditional bioproduction methods.

The eXoZymes platform represents what the company describes as a historic first in biomanufacturing by freeing enzyme-driven chemical reactions from cellular limitations. This cell-free approach utilizes advanced enzymes called exozymes that are enhanced through artificial intelligence and bioengineering to function in bioreactors without living cells. The technology transforms biomass into essential natural products, medicines, chemicals, and biofuels, offering partners a commercially viable path to scalable and sustainable production of small molecules at industrial scale.

David Shapiro, CEO of B2i Digital, emphasized the significance of eXoZymes' technology in addressing current industry challenges. The platform specifically targets the scale-up bottleneck observed in first-generation synthetic biology, positioning the company as an attractive opportunity for investors focused on sustainable industrial biotechnology. According to Shapiro, the technology aims to replace selected petrochemical processes with lower-impact biosolutions, addressing growing environmental concerns in industrial manufacturing.

Michael Heltzen, CEO of eXoZymes, characterized the company's work as leading the fourth industrial revolution at the intersection of biology and technology. The partnership with B2i Digital will enhance the company's visibility among investors who understand the value of their scalable enzyme-based approach as an alternative to petrochemical processes, natural extraction, and synthetic biology. Heltzen expressed confidence that cell-free technology represents the next generation of biomanufacturing.

The company initially targets low volume, high value natural products with potential pharmaceutical applications, indicating a strategic focus on high-margin markets where their technology can provide competitive advantages. This approach allows eXoZymes to demonstrate the commercial viability of their platform while building toward broader industrial applications.

B2i Digital brings substantial resources to the partnership, including its proprietary network of over 1.4 million market participants and deep experience in supporting investor conferences. The firm blends digital marketing technology with capital markets expertise to deliver boardroom-caliber investor engagement and provide growth companies with institutional-quality exposure through its Featured Conference, Featured Company, and Featured Expert programs. More information about B2i Digital's services can be found at https://b2idigital.com.

eXoZymes' technology platform offers partners access to design and run enzyme pathways to produce target chemicals, providing a scalable alternative to traditional manufacturing methods. The company maintains an online presence at https://exozymes.com where interested parties can learn more about their innovative approach to biomanufacturing. This partnership represents an important step in bringing advanced biotechnological solutions to market that could significantly reduce the environmental impact of industrial chemical production while maintaining commercial viability.